Testosterone Is Sure Looking Virile Oct 31, 2009
When Endo Pharmaceuticals () acquired two experimental testosterone products earlier this year, CEO David P. Holveck predicted that safety issues might delay approval by the U.S. Food Administration. Synthetic versions of the quintessential male hormone are prescribed to thousands of patients in the U.S. to treat fatigue, sagging libido, and other signs of testosterone deficiency. (BusinessWeek)
Redefining Growth Oct 31, 2009
Microsoft (), Google (), Panera Bread (), Staples (), Juniper Networks, Nike , and Endo Pharmaceuticals are just a few of America's exceptional growth companies that have managed to turn big ideas into billion-dollar revenue businesses. This elite set of companies is the heart of America's innovation and growth. (BusinessWeek)
Bioniche Reports Fiscal 2009 Year-End Results Sep 19, 2009
"We had a very successful year in terms of revenues generated by our base Animal Health business, experiencing 21% growth in a challenging global economy," said Graeme McRae, Chairman, President CEO of Bioniche Life Sciences Inc. "In addition, subsequent to the end of the fiscal year, we announced a transformative corporate event: The signing of a licensing agreement with Endo Pharmaceuticals Inc. for exclusive rights to develop and market UrocidinTM in the U.S. with an option for global... (PR Newswire)
FDA taking more time to review Endo drug Sep 3, 2009
David Holveck, president and CEO of Endo Pharmaceuticals, said, We believe our application fully supports the approval of this therapy. Hypogonadism, characterized by low testosterone levels, is a common yet largely under-recognized and under-treated condition that afflicts an estimated 13. (Philadelphia Business Journal, PA)
Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 Sep 1, 2009
Aug. 31 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ) announced today that it will present at the Thomas Weisel Partners Healthcare Conference 2009 on Thursday, Sept. 10, 2009, at 2:40 p.m. EDT. Alan Levin, Chief Financial Officer of Endo, will review the company's products and development programs ... Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat... (PR Newswire)
GSK seems to dismiss HGS rumour Aug 27, 2009
8 per cent to 148p after striking a licensing and distribution agreement with Endo Pharmaceuticals for its testosterone replacement gel Fortigel. IP Group, the intellectual property commercialisation company, added 15. (FT.com -- Markets)
Endo buys rights to ProStrakan testosterone replacement gel Fortesta Aug 27, 2009
Endo Pharmaceuticals (NASDAQ:ENDP) of Chadds Ford, Pa ... ProStrakan will exclusively supply Fortesta to Endo Pharmaceuticals in the United States for an undisclosed supply price. (Philadelphia Business Journal, PA)
FDA panel: Lower maximum daily dose of Tylenol Jul 5, 2009
Vicodin is marketed by Abbott Laboratories, while Percocet is marketed by Endo Pharmaceuticals. Both painkillers also are available in cheaper generic versions. (Yahoo News -- Pharmaceutical Industry News)
J&J and Wyeth Bring the Pain Jul 2, 2009
The FDA panel also voted in favor of recalling prescription drugs containing acetaminophen, such as Abbott Laboratories' () Vicodin and Endo Pharmaceuticals' () Percocet. The branded versions and their generic counterparts were prescribed 124 million times last year, making them the most popular class of prescription drug on the market. (BusinessWeek)
Experts Urge Stronger Limits for Some Pain Drugs Jul 2, 2009
The advisers urged a ban on prescription painkillers that include acetaminophen, such as Abbott Laboratories' Vicodin and Endo Pharmaceuticals' Percocet -- two drugs that combine acetaminophen with powerful opioids. If the agency decides against a recall, panelists said it should at least require a strong "black-box" warning on such combination products, also made by Watson Pharmaceuticals Inc and Covidien Plc's Mallinckrodt unit. (MEDLINEplus)
FDA advisers vote to take Vicodin... Jul 2, 2009
Endo Pharmaceuticals, which makes the brand-name Percocet, did not immediately return a phone call seeking comment. Percocet is also available as a generic. (CNN -- Law)
Penwest Announces That the Results of Its Annual Meeting Have Been Certified Jun 25, 2009
" About Penwest Pharmaceuticals Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. Penwest is currently developing A0001, a coenzyme Q analog drug candidate for inherited mitochondrial respiratory chain diseases. Penwest is also applying its drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations with... (Primezone Releases)
Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference Jun 6, 2009
June 5 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ) announced today that it will present at the Goldman Sachs 30th Annual Healthcare Conference on Wednesday, June 10, 2009 at 4:30 pm Eastern Time ... Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, overactive bladder, prostate cancer and the early onset of puberty in children, or... (PR Newswire)
Endo Announces Compensation for New CFO Alan Levin May 30, 2009
May 29 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ) announced today that the company is granting Alan Levin a sign-on award of 43,500 restricted stock units and an option to purchase 80,000 shares of Endo common stock in connection with his appointment as Endo's executive vice president and chief financial officer ... Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals... (PR Newswire)
Washington State Court Denies Dissidents' Request for Preliminary Injunction in Penwest Proxy Vote May 23, 2009
Important factors that could cause results to differ materially include: risks relating to the commercial success of Opana ER, including our reliance on Endo Pharmaceuticals Inc. for the commercial success of Opana ER and risks of generic competition; the need for capital; regulatory risks relating to drugs in development, including the timing and outcome of regulatory submissions and regulatory actions; uncertainty of success of collaborations; the timing of clinical trials; whether the results... (Primezone Releases)
Teikoku Pharma USA Acquires Travanti Pharma Inc. May 8, 2009
Teikoku focuses its efforts in two therapeutic areas; Pain Management and CNS. Teikoku's main product is Lidoderm(R) (Lidocaine 5% Patch) for PHN, in collaboration with Endo Pharmaceuticals in the US, Grunenthal GmbH in Europe, Mundipharma in South East Asia and SK Pharma for Korea. Teikoku's commitment is to expand transdermal technologies for the benefit of patients and partners. (PR Newswire)
> Business Profile: TheUegroup is a small company with big designs Apr 2, 2009
CUSTOMERS: Consumer and Web products customers include Dell Inc., Hewlett-Packard Co., Plastic Logic Ltd., Food Network, McAfee Inc., Cisco Systems Inc./WebEx, Epson Corp., Nokia and Juniper Networks Inc. Health care customers include Boston Scientific Corp., Smith & Nephew Orthopaedics, Endo Pharmaceuticals Inc., Allergan Inc. and Laerdal Medical AS.. LOCATIONS: Two. (San Jose Business Journal, CA)
Endo Pharmaceuticals Appoints Dr. Nancy Hutson to Board of Directors Apr 1, 2009
March 30 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ) announced today the appointment of Nancy J. Hutson, Ph ... Roger Kimmel, chairman of the board of Endo Pharmaceuticals, stated: "We are pleased to have Nancy Hutson join our board and bring her vast pharmaceutical knowledge and experience to our company. We welcome her contributions to our future success as we expand our product pipeline and therapeutic focus." ... Endo Pharmaceuticals is a specialty pharmaceutical company... (PR Newswire)
Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6.25% Convertible Senior Notes Due 2009 Mar 26, 2009
Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6 ... Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6 ... March 25 /PRNewswire/ -- Endo Pharmaceuticals Solutions Inc. (formerly known as Indevus Pharmaceuticals, Inc.) today commenced an offer to purchase any or all of its outstanding 6. (PR Newswire)
New Publication Describes Program for Monitoring Prescription Drug Abuse, Managing Risk Feb 23, 2009
NAVIPPRO was developed by Inflexxion with support from the National Institute on Drug Abuse (NIDA), and industry support from Endo Pharmaceuticals, Inc. and Alpharma Pharmaceuticals LLC. With our ongoing research and product development, NAVIPPRO is constantly evolving to meet Inflexxion's goal of advancing public health. To learn more about the program, visit the NAVIPPRO website (). (Yahoo News -- Press Releases)
Endo and Penwest Announce Settlement of Opana(R) ER Litigation Feb 21, 2009
Feb. 20 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ), and Penwest Pharmaceuticals (Nasdaq: ) announced today that the companies have settled litigation with Actavis South Atlantic LLC regarding the production and sale of generic formulations of Opana(R) ER (oxymorphone hydrochloride) Extended Release Tablets CII. Endo and Penwest have agreed to dismiss their suit with prejudice and Actavis has agreed to dismiss its counterclaims with prejudice ... Endo Pharmaceuticals is a specialty... (PR Newswire)
Finkelstein Thompson LLP Announces Investigation Into Indevus Pharmaceuticals Feb 8, 2009
WASHINGTON, Feb. 6, 2009 (GLOBE NEWSWIRE) -- Finkelstein Thompson LLP is investigating claims that Indevus Pharmaceuticals Inc. (NasdaqGM: - ) board members have breached their fiduciary duty to the corporation and its shareholders in connection with Endo Pharmaceuticals' proposed tender offer for all outstanding shares of Indevus' common stock. The investigation is focused on allegations that the price is inadequate, that the Indevus Board of Directors has agreed to overly-restrictive deal... (Primezone Releases)
